Hematology · RAS-associated autoimmune leukoproliferative disease

The Biology of RALD: Why Cells Overgrow

At a Glance

RALD is caused by an acquired NRAS or KRAS mutation that keeps growth signals active, allowing some immune cells to survive and multiply. Diagnosis requires more than finding the mutation: doctors assess persistent high monocyte counts, immune findings, and tests that help exclude JMML.

Understanding the biology of RAS-associated autoimmune leukoproliferative disease (RALD) is key to navigating the diagnostic process. While it shares many physical symptoms with other conditions, RALD is defined by a specific “instructional error” in the body’s white blood cells, alongside specific clinical features.

The Biological “Glitch”: Overactive Signaling

In a healthy immune system, cells receive constant signals telling them when to grow and when to stop. In RALD, a somatic activating mutation occurs in either the NRAS or KRAS gene ^[1]^[2]. These genes act like an “on-off” switch for cell growth.

When these genes are mutated, the switch gets stuck in the “on” position. This leads to hyperactive signaling through a pathway called MAPK/ERK ^[3]^[4]. Instead of dying off when their job is done, certain white blood cells—particularly monocytes and certain T cells—continue to survive and multiply ^[5]^[6].

RALD vs. Classical ALPS

While RALD is an “ALPS-like” disorder, its biology is fundamentally different from Classical ALPS (Autoimmune Lymphoproliferative Syndrome):

Classical ALPS is caused by a defect in the FAS pathway, which is the body’s “cell suicide” (apoptosis) program ^[7]. The cells don’t die because the “kill” signal is broken. Classical ALPS is distinguished by checking for specific FAS gene mutations ^[8].
RALD is caused by the RAS pathway being too active ^[9]. The cells don’t die because they are receiving too many “stay alive and grow” signals ^[5].

Because RALD is so rare, it is often mistaken for other ALPID disorders (a wide range of “ALPS-like” immune dysregulation disorders caused by other genes like STAT3, CTLA4, or PI3K) ^[10]^[11]. A broad genetic panel is often the best way to rule these out.

Diagnostic Context: It’s More Than Just a Mutation

It is important to understand that finding an NRAS or KRAS mutation is not the only step in diagnosing RALD. These exact same mutations can also be found in serious blood cancers like Juvenile Myelomonocytic Leukemia (JMML) ^[12]. A diagnosis of RALD relies on a complete clinical picture evaluated by an expert team, including:

Persistent Monocytosis: One of the most common signs of RALD is an elevated count of monocytes (a type of white blood cell) that stays high for months ^[1]^[13].
Autoimmune Cytopenias: This occurs when the overactive immune system mistakenly attacks the body’s own healthy blood cells, leading to low red blood cells (anemia) or low platelets (thrombocytopenia) ^[1].
Hypergammaglobulinemia: This is an abnormally high level of antibodies in the blood, indicating the immune system is in “overdrive” ^[14].
Double-Negative T Cells (DNTs): These unusual T cells (TCRαβ+ CD4- CD8-) are a hallmark of Classical ALPS ^[7]. While some children with RALD also have high DNT counts, they are not specific to RALD and serve as just one contextual data point ^[15]^[16].
Blood Smear and Bone Marrow Evaluation: Specialists will look closely at the cells under a microscope to ensure there are no excess immature cells (blasts) that would indicate a progression toward a condition like JMML ^[12].

The Role of Genetic Testing

To help confirm the diagnosis, your team will perform specialized genetic tests to look for the somatic mutation. Because the mutation only exists in a fraction of blood cells, detection can be complex ^[17].

Whole Blood Testing: Often, a standard blood test utilizing high-depth sequencing is enough to find the mutation ^[16]^[18].
Targeted Assays: If a blood test is negative but symptoms are strong, doctors may use highly sensitive sequencing or sort the blood into different cell types (like monocytes) to find mutations that may only be present in a tiny fraction of the cells (low Variant Allele Fraction or VAF) ^[19]^[20].

A negative blood test does not necessarily mean a bone marrow biopsy is required; the decision for invasive testing depends on the broader clinical question and should be directed by your treating team.

Common questions in this guide

What causes RALD?

RALD is caused by an acquired, or somatic, activating change in the NRAS or KRAS gene in some blood cells. This change keeps the RAS/MAPK growth pathway too active, so certain immune cells survive and multiply instead of shutting down when their job is finished.

How is RALD different from classical ALPS?

Both conditions can cause immune overactivity and abnormal lymphocyte growth, but their underlying problems differ. RALD involves excessive RAS signaling from an NRAS or KRAS mutation, whereas classical ALPS involves a defect in the FAS cell-death pathway.

Does finding an NRAS or KRAS mutation confirm RALD?

No. The same mutations can occur in juvenile myelomonocytic leukemia, or JMML, so doctors must consider the full clinical picture. Persistent monocytosis, autoimmune cytopenias, antibody levels, blood-smear findings, and sometimes bone marrow evaluation help distinguish RALD from a myeloid cancer.

What genetic tests are used to diagnose RALD?

High-depth sequencing of whole blood may detect the somatic NRAS or KRAS mutation. If the mutation is present in only a small fraction of cells, doctors may use more sensitive testing or analyze separated cell types such as monocytes. A negative blood test does not automatically mean a bone marrow biopsy is needed.

What does a high double-negative T-cell count mean in RALD?

Double-negative T cells are T cells that lack the usual CD4 and CD8 markers and are a classic clue to classical ALPS. Some children with RALD can also have more of these cells, so a high count is not specific and must be interpreted with genetic and clinical findings.

Are MEK inhibitors a treatment for RALD?

MEK inhibitors are being researched for RALD because the condition involves overactive RAS signaling. They are investigational in this context, so ask the treating team whether a targeted therapy study or clinical trial applies to the specific mutation.

Get notified when new evidence is published on Dianzani autoimmune lymphoproliferative disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (20)

1
Clinical Spectrum of Ras-Associated Autoimmune Leukoproliferative Disorder (RALD).
Neven Q, Boulanger C, Bruwier A, et al.
Journal of clinical immunology 2021; (41(1)):51-58 doi:10.1007/s10875-020-00883-7.
PMID: 33011939
2
Type I interferon activation in RAS-associated autoimmune leukoproliferative disease (RALD).
Papa R, Rusmini M, Schena F, et al.
Clinical immunology (Orlando, Fla.) 2021; (231()):108837 doi:10.1016/j.clim.2021.108837.
PMID: 34455097
3
Diffuse Large B-cell lymphoma in a Ras-Associated Autoimmune Leukoproliferative Disorder (RALD).
Sun C, Zhao L, Xia J, et al.
Annals of hematology 2025; (104(11)):6109-6113 doi:10.1007/s00277-025-06555-z.
PMID: 41114813
4
Status of KRAS in iPSCs Impacts upon Self-Renewal and Differentiation Propensity.
Kubara K, Yamazaki K, Ishihara Y, et al.
Stem cell reports 2018; (11(2)):380-394 doi:10.1016/j.stemcr.2018.06.008.
PMID: 29983389
5
Monoallelic KRAS (G13C) mutation triggers dysregulated expansion in induced pluripotent stem cell-derived hematopoietic progenitor cells.
Lin HT, Takagi M, Kubara K, et al.
Stem cell research & therapy 2024; (15(1)):106 doi:10.1186/s13287-024-03723-2.
PMID: 38627844
6
T and B cell clonal expansion in Ras-associated lymphoproliferative disease (RALD) as revealed by next-generation sequencing.
Levy-Mendelovich S, Lev A, Rechavi E, et al.
Clinical and experimental immunology 2017; (189(3)):310-317 doi:10.1111/cei.12986.
PMID: 28500641
7
Immunologic evaluation and genetic defects of apoptosis in patients with autoimmune lymphoproliferative syndrome (ALPS).
Casamayor-Polo L, López-Nevado M, Paz-Artal E, et al.
Critical reviews in clinical laboratory sciences 2021; (58(4)):253-274 doi:10.1080/10408363.2020.1855623.
PMID: 33356695
8
Key diagnostic markers for autoimmune lymphoproliferative syndrome with molecular genetic diagnosis.
Molnár E, Radwan N, Kovács G, et al.
Blood 2020; (136(17)):1933-1945 doi:10.1182/blood.2020005486.
PMID: 32599613
9
Severe RAS-Associated Lymphoproliferative Disease Case with Increasing αβ Double-Negative T Cells with Atypical Features.
Kurita D, Shiba N, Ohya T, et al.
Journal of clinical immunology 2023; (43(8)):1992-1996 doi:10.1007/s10875-023-01566-9.
PMID: 37644277
10
Diagnostic evaluation of paediatric autoimmune lymphoproliferative immunodeficiencies (ALPID): a prospective cohort study.
Hägele P, Staus P, Scheible R, et al.
The Lancet. Haematology 2024; (11(2)):e114-e126 doi:10.1016/S2352-3026(23)00362-9.
PMID: 38302222
11
Primary Immune Regulatory Disorders With an Autoimmune Lymphoproliferative Syndrome-Like Phenotype: Immunologic Evaluation, Early Diagnosis and Management.
López-Nevado M, González-Granado LI, Ruiz-García R, et al.
Frontiers in immunology 2021; (12()):671755 doi:10.3389/fimmu.2021.671755.
PMID: 34447369
12
Juvenile Myelomonocytic Leukemia Presenting with Unusual Immunonologic Manifestations: Report of a Case with Multiple Somatic Genetic Aberrations Including KRAS and Novel ETV6 Mutations.
Brannock KR, Kaumeyer B, Nicol KK, et al.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2026; 10935266261466228 doi:10.1177/10935266261466228.
PMID: 42423368
13
JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities.
Calvo KR, Price S, Braylan RC, et al.
Blood 2015; (125(18)):2753-8 doi:10.1182/blood-2014-11-567917.
PMID: 25691160
14
[Ras-associated autoimmune leukoproliferative disorder: a report of 2 cases and literature review].
He TY, Li CR, Xia Y, et al.
Zhonghua er ke za zhi = Chinese journal of pediatrics 2017; (55(11)):853-857 doi:10.3760/cma.j.issn.0578-1310.2017.11.013.
PMID: 29141318
15
Somatic mosaicism for a NRAS mutation associates with disparate clinical features in RAS-associated leukoproliferative disease: a report of two cases.
Shiota M, Yang X, Kubokawa M, et al.
Journal of clinical immunology 2015; (35(5)):454-8 doi:10.1007/s10875-015-0163-3.
PMID: 25896945
16
Idiopathic splenomegaly in childhood and the spectrum of RAS-associated lymphoproliferative disease: a case report.
Blanchard-Rohner G, Ragotte RJ, Junker AK, et al.
BMC pediatrics 2021; (21(1)):45 doi:10.1186/s12887-021-02508-3.
PMID: 33472608
17
RAS-associated Autoimmune Leukoproliferative disease (RALD) manifested with early-onset SLE-like syndrome: a case series of RALD in Chinese children.
Wang W, Zhou Y, Zhong L, et al.
Pediatric rheumatology online journal 2019; (17(1)):55 doi:10.1186/s12969-019-0346-1.
PMID: 31412876
18
Detection and evolutionary dynamics of somatic FAS variants in autoimmune lymphoproliferative syndrome: Diagnostic implications.
Batlle-Masó L, Garcia-Prat M, Parra-Martínez A, et al.
Frontiers in immunology 2022; (13()):1014984 doi:10.3389/fimmu.2022.1014984.
PMID: 36466883
19
Cutaneous involvement in an 8-year-old boy with Ras-associated autoimmune leucoproliferative disorder (RALD).
Giacaman A, Bauzá Alonso A, Salinas Sanz JA, et al.
Clinical and experimental dermatology 2018; (43(8)):913-916 doi:10.1111/ced.13668.
PMID: 29908030
20
Mosaic variants in KRAS and STAT5B associated with a mixed phenotype of 2 acquired errors of immunity.
Forkgen J, Masle-Farquhar E, Fontaine Y, et al.
The Journal of allergy and clinical immunology 2026; (157(5)):1218-1223.e3 doi:10.1016/j.jaci.2026.01.018.
PMID: 41628732

This page is for informational purposes only and does not constitute medical advice. A hematology, immunology, or genetics team should interpret your results and guide RALD testing.

Guide Contents